{"id":"https://openalex.org/W7225590303","doi":"https://doi.org/10.1007/s13555-026-01973-x","title":"Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study","display_name":"Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study","alternate_titles":[],"publication_year":2026,"publication_date":"2026-11-08","ids":{"openalex":"https://openalex.org/W7225590303","doi":"https://doi.org/10.1007/s13555-026-01973-x","pmid":"https://pubmed.ncbi.nlm.nih.gov/42999962"},"language":"en","primary_location":{"id":"doi:10.1007/s13555-026-01973-x","doi":"https://doi.org/10.1007/s13555-026-01973-x","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13555-026-01973-x","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13555-026-01973-x.pdf","source":{"id":"https://openalex.org/S4210222097","display_name":"Dermatology and Therapy","issn_l":"2190-9172","issn":["2190-9172","2193-8210"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Dermatology and Therapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W7225590303"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://link.springer.com/content/pdf/10.1007/s13555-026-01973-x.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014869039","display_name":"Eugenia Veronica Di Brizzi","orcid":"https://orcid.org/0000-0002-0278-2443","observed_orcids":["https://orcid.org/0000-0002-0278-2443"]},"institutions":[{"id":"https://openalex.org/I197809005","display_name":"University of Campania \"Luigi Vanvitelli\"","ror":"https://ror.org/02kqnpp86","country_code":"IT","type":"education","lineage":["https://openalex.org/I197809005"]}],"countries":["IT"],"is_corresponding":true,"raw_author_name":"Eugenia Veronica Di Brizzi","raw_affiliation_strings":["Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy. eugeniaveronica.dibrizzi@gmail.com"],"raw_orcid":"https://orcid.org/0000-0002-0278-2443","affiliations":[{"raw_affiliation_string":"Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy. eugeniaveronica.dibrizzi@gmail.com","institution_ids":["https://openalex.org/I197809005"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5116076153","display_name":"Carlo Panetti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I197809005","display_name":"University of Campania \"Luigi Vanvitelli\"","ror":"https://ror.org/02kqnpp86","country_code":"IT","type":"education","lineage":["https://openalex.org/I197809005"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Panetti Carlo","raw_affiliation_strings":["Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy","institution_ids":["https://openalex.org/I197809005"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018473641","display_name":"Maria Maddalena Nicoletti","orcid":"https://orcid.org/0009-0000-8580-606X","observed_orcids":["https://orcid.org/0009-0000-8580-606X"]},"institutions":[{"id":"https://openalex.org/I197809005","display_name":"University of Campania \"Luigi Vanvitelli\"","ror":"https://ror.org/02kqnpp86","country_code":"IT","type":"education","lineage":["https://openalex.org/I197809005"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Maria Maddalena Nicoletti","raw_affiliation_strings":["Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy","institution_ids":["https://openalex.org/I197809005"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025150226","display_name":"Paolino FRANZESE","orcid":"https://orcid.org/0009-0006-4190-6193","observed_orcids":["https://orcid.org/0009-0006-4190-6193"]},"institutions":[{"id":"https://openalex.org/I197809005","display_name":"University of Campania \"Luigi Vanvitelli\"","ror":"https://ror.org/02kqnpp86","country_code":"IT","type":"education","lineage":["https://openalex.org/I197809005"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Paolino Franzese","raw_affiliation_strings":["Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy","institution_ids":["https://openalex.org/I197809005"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059348648","display_name":"Stefano Caccavale","orcid":"https://orcid.org/0000-0001-7433-9283","observed_orcids":["https://orcid.org/0000-0001-7433-9283"]},"institutions":[{"id":"https://openalex.org/I197809005","display_name":"University of Campania \"Luigi Vanvitelli\"","ror":"https://ror.org/02kqnpp86","country_code":"IT","type":"education","lineage":["https://openalex.org/I197809005"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Stefano Caccavale","raw_affiliation_strings":["Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy","institution_ids":["https://openalex.org/I197809005"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072653864","display_name":"Giuseppe Argenziano","orcid":"https://orcid.org/0000-0003-1413-8214","observed_orcids":["https://orcid.org/0000-0003-1413-8214"]},"institutions":[{"id":"https://openalex.org/I197809005","display_name":"University of Campania \"Luigi Vanvitelli\"","ror":"https://ror.org/02kqnpp86","country_code":"IT","type":"education","lineage":["https://openalex.org/I197809005"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Giuseppe Argenziano","raw_affiliation_strings":["Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy","institution_ids":["https://openalex.org/I197809005"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5054555628","display_name":"Anna Balato","orcid":"https://orcid.org/0000-0001-5485-0172","observed_orcids":["https://orcid.org/0000-0001-5485-0172"]},"institutions":[{"id":"https://openalex.org/I197809005","display_name":"University of Campania \"Luigi Vanvitelli\"","ror":"https://ror.org/02kqnpp86","country_code":"IT","type":"education","lineage":["https://openalex.org/I197809005"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Anna Balato","raw_affiliation_strings":["Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Via Pansini 5, 80131, Naples, Italy","institution_ids":["https://openalex.org/I197809005"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5014869039"],"corresponding_institution_ids":["https://openalex.org/I197809005"],"apc_list":{"value":7400,"currency":"USD","value_usd":7400},"apc_paid":{"value":7400,"currency":"USD","value_usd":7400},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tildrakizumab","display_name":"tildrakizumab","score":0.9940000176429749},{"id":"https://openalex.org/keywords/moderate-to-severe-plaque-psoriasis","display_name":"moderate-to-severe plaque psoriasis","score":0.8410000205039978},{"id":"https://openalex.org/keywords/switching-biologic-therapy","display_name":"biologic therapy switching","score":0.7620000243186951},{"id":"https://openalex.org/keywords/il-23-inhibitors","display_name":"IL-23 inhibitors","score":0.9620000123977661},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.8420000076293945},{"id":"https://openalex.org/keywords/pasi-response","display_name":"PASI response","score":0.7739999890327454},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.9789999723434448},{"id":"https://openalex.org/keywords/treatment-satisfaction","display_name":"treatment satisfaction","score":0.6919999718666077},{"id":"https://openalex.org/keywords/dermatology-life-quality-index","display_name":"Dermatology Life Quality Index","score":0.8550000190734863},{"id":"https://openalex.org/keywords/who-5-well-being","display_name":"WHO-5 well-being","score":0.7490000128746033}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9473999738693237},{"id":"https://openalex.org/C2777011040","wikidata":"https://www.wikidata.org/wiki/Q390643","display_name":"Psoriasis Area and Severity Index","level":3,"score":0.7494000196456909},{"id":"https://openalex.org/C2776173921","wikidata":"https://www.wikidata.org/wiki/Q25326609","display_name":"Dermatology Life Quality Index","level":3,"score":0.6452999711036682},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5947999954223633},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.5224999785423279},{"id":"https://openalex.org/C188816634","wikidata":"https://www.wikidata.org/wiki/Q2113324","display_name":"Prospective cohort study","level":2,"score":0.47049999237060547},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.43720000982284546},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4154999852180481},{"id":"https://openalex.org/C30036603","wikidata":"https://www.wikidata.org/wiki/Q17125150","display_name":"Severity of illness","level":2,"score":0.36809998750686646},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3668000102043152},{"id":"https://openalex.org/C3020604521","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Plaque psoriasis","level":3,"score":0.28459998965263367},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.267300009727478},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.2637999951839447}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1007/s13555-026-01973-x","doi":"https://doi.org/10.1007/s13555-026-01973-x","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13555-026-01973-x","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13555-026-01973-x.pdf","source":{"id":"https://openalex.org/S4210222097","display_name":"Dermatology and Therapy","issn_l":"2190-9172","issn":["2190-9172","2193-8210"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Dermatology and Therapy","raw_type":"journal-article"},{"id":"pmid:42999962","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42999962","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Dermatology and therapy","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1007/s13555-026-01973-x","doi":"https://doi.org/10.1007/s13555-026-01973-x","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s13555-026-01973-x","pdf_url":"https://link.springer.com/content/pdf/10.1007/s13555-026-01973-x.pdf","source":{"id":"https://openalex.org/S4210222097","display_name":"Dermatology and Therapy","issn_l":"2190-9172","issn":["2190-9172","2193-8210"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","ki-jl-1","norway-1","oarl","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Dermatology and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225590303.pdf","grobid_xml":"https://content.openalex.org/works/W7225590303.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W1692288477","https://openalex.org/W2021018799","https://openalex.org/W2075361812","https://openalex.org/W2096991001","https://openalex.org/W2121126920","https://openalex.org/W2623888527","https://openalex.org/W2792924793","https://openalex.org/W2973127305","https://openalex.org/W2999032467","https://openalex.org/W3023395948","https://openalex.org/W3124008657","https://openalex.org/W3162925909","https://openalex.org/W3206647100","https://openalex.org/W3213975960","https://openalex.org/W4293003987","https://openalex.org/W4295411331","https://openalex.org/W4297250253","https://openalex.org/W4388128802","https://openalex.org/W4389340796","https://openalex.org/W4396700658","https://openalex.org/W4396731084","https://openalex.org/W4403684448","https://openalex.org/W4405988458","https://openalex.org/W4409697726","https://openalex.org/W4411747081","https://openalex.org/W7125485554"],"related_works":["https://openalex.org/W7169473171","https://openalex.org/W7171835521","https://openalex.org/W4396700658","https://openalex.org/W4404287212","https://openalex.org/W4389340796","https://openalex.org/W4388128802","https://openalex.org/W7221325116","https://openalex.org/W7169665823","https://openalex.org/W4223474344","https://openalex.org/W7167906081"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Switching":[1,226],"between":[2],"biologic":[3],"therapies":[4],"is":[5],"a":[6,73,258],"common":[7],"strategy":[8],"in":[9,51,106,192,233],"the":[10,38,220,255,268,272],"management":[11],"of":[12,59,171,203,257,271],"moderate-to-severe":[13,54],"psoriasis":[14,56],"after":[15,57,229],"treatment":[16,199],"failure.":[17],"However,":[18],"prospective":[19,66],"real-world":[20,67],"data":[21],"on":[22,262],"switching":[23,48],"from":[24,158,244],"interleukin":[25],"(IL)-17":[26],"inhibitors":[27,30],"to":[28,36,49,79,162,213,227,246],"IL-23":[29],"remain":[31],"limited.":[32],"This":[33],"study":[34],"aimed":[35],"evaluate":[37],"clinical":[39,149,235],"effectiveness,":[40],"patient-reported":[41,114,237],"outcomes,":[42],"and":[43,81,90,94,103,111,113,127,139,143,147,177,194,236],"dose":[44,222],"selection":[45],"associated":[46],"with":[47,53,153,216],"tildrakizumab":[50,80,228],"patients":[52,70,172,204,218],"plaque":[55],"failure":[58,231],"IL-17":[60,75],"inhibitor":[61,76],"therapies.":[62],"METHODS:":[63],"In":[64],"this":[65],"study,":[68],"30":[69],"who":[71],"failed":[72],"single":[74],"were":[77,135,189,210],"switched":[78],"followed":[82],"for":[83,132],"52":[84,240],"weeks.":[85,241],"Clinical":[86],"outcomes":[87,115],"(Psoriasis":[88],"Area":[89],"Severity":[91],"Index":[92,119,125],"[PASI]":[93],"Physician":[95],"Global":[96],"Assessment":[97],"[PGA]),":[98],"response":[99],"rates":[100],"(75%,":[101],"90%,":[102],"100%":[104],"improvement":[105,150],"PASI":[107,155,183],"score":[108],"[PASI75,":[109],"PASI90,":[110,176],"PASI100]),":[112],"(Dermatology":[116],"Life":[117],"Quality":[118],"[DLQI],":[120],"World":[121],"Health":[122],"Organization-Five":[123],"Well-Being":[124],"[WHO-5],":[126],"nine-item":[128],"Treatment":[129],"Satisfaction":[130],"Questionnaire":[131],"Medication":[133],"[TSQM-9])":[134],"assessed":[136],"at":[137,160,164],"baseline":[138,161],"weeks":[140],"4,":[141],"16,":[142],"52.":[144,166],"RESULTS:":[145],"Rapid":[146],"sustained":[148],"was":[151,249],"observed,":[152],"mean":[154],"scores":[156,184],"decreasing":[157],"12.2":[159],"1.1":[163],"week":[165,168],"At":[167],"52,":[169],"88.9%":[170],"achieved":[173],"PASI75,":[174],"66.7%":[175],"50%":[178],"PASI100,":[179],"while":[180],"94.4%":[181],"reached":[182],"\u2264":[185],"3.":[186],"Significant":[187],"improvements":[188],"also":[190],"observed":[191,251],"DLQI":[193],"WHO-5":[195],"scores,":[196],"alongside":[197],"high":[198],"satisfaction.":[200],"Although":[201],"46.7%":[202],"initially":[205],"received":[206],"100":[207,245,263],"mg,":[208,215],"all":[209],"subsequently":[211],"escalated":[212],"200":[214,247],"no":[217],"maintaining":[219],"lower":[221],"throughout":[223],"follow-up.":[224],"CONCLUSIONS:":[225],"anti-IL-17":[230],"resulted":[232],"significant":[234],"benefits":[238],"over":[239],"Dose":[242],"escalation":[243],"mg":[248,264],"frequently":[250],"during":[252],"follow-up;":[253],"however,":[254],"absence":[256],"comparator":[259],"group":[260],"maintained":[261],"precludes":[265],"conclusions":[266],"regarding":[267],"comparative":[269],"effectiveness":[270],"two":[273],"dosing":[274],"regimens.":[275]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W7225590303","counts_by_year":[],"updated_date":"2026-11-13T13:42:25.865203","created_date":"2026-11-09T00:00:00"}
